NeoTX

13 articles with NeoTX

• 

  Clinical Catch-Up: NIH's COVID-19 Trial and All About ASCO

  6/6/2022

  It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.

• NeoTX announces successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP), in combination with docetaxel in advanced non-small cell lung cancer (NSCLC)

  6/1/2022

  NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, announced today the successful completion of the first stage of a Simon 2 stage Phase 2a clinical trial of naptumomab estafenatox (NAP).

• NeoTX Acquires InterX, Adds World Class Discovery Arm

  5/12/2022

  NeoTX announced the acquisition of InterX. InterX, is a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel Prize Laureate Prof Michael Levitt's discoveries.

• Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)

  10/20/2021

  Active Biotech and its partner NeoTX announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox, in combination with docetaxel in patients with advanced non-small cell lung cancer.

• Active Biotech AB Interim report January – June 2021

  8/5/2021

  Active Biotech and NeoTX announce FDA clearance of IND for phase II clinical trial of naptumomab

• NeoTX Hosting Key Opinion Leader Webinar on Overcoming Check Point Inhibitor ResistanceWebinar on Wednesday, July 14th @ 10amET

  7/7/2021

  NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14, 2021 at 10am Eastern Time.

• NeoTX Announces FDA Clearance of IND for Phase 2 Clinical Trial of Naptumomab Estafenatox (NAP), its lead Tumor Targeted Superantigen Candidate

  4/19/2021

  Phase 2a trial in non-small cell lung cancer expected to begin enrollment in the US in the second half of 2021

• NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium

  8/3/2020

  NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted cancer immunotherapies, today announced it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place August 4-5, 2020. Chief Executive Officer, Asher Nathan, will deliver a corporate update to potential investors and strategic partners, among other various re

• NeoTX Closes $45 Million Series C Financing

  2/19/2020

  NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection platform to develop targeted anticancer immunotherapies, has closed a $45 million Series C financing.

• NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

  11/4/2019

  NeoTX Therapeutics, Ltd. announced a presentation on the company’s lead candidate from its Selective T cell Redirection platform, naptumomab estafenatox, at the Society for Immunotherapy of Cancer’s 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland.

• 

  Clinical Catch-Up: October 28-Nov 1

  11/4/2019

  Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.

• NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors

  10/28/2019

  NeoTX Therapeutics, Ltd. announced the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox in combination with AstraZeneca’s checkpoint inhibitor IMFINZI® for the treatment of advanced or metastatic solid tumors.

• Active Biotech, NeoTX Ink $71 Million+ Immuno-Oncology Pact

  10/26/2016